Investor Relations

Corporate Presentation

View our latest Corporate Presentation to find the most recent investor-related information.

View Latest Corporate Presentation

Designing A New Regenerative Platform

  • A single patented formulation, engineered for multi-market scale.
  • An efficient regulatory path to staged, multi-market clearance.
  • One core asset, five potential revenue streams.
  • All rights, title, and interest in the platform IP.
  • 100% owned IP across 40+ countries, anchored by more than a decade of validated preclinical science.
One platform technology with broad potential across regenerative medicine, wound care, and aesthetic restoration

CXU is building to scale in multiple high-value markets with the potential of additional revenue streams

Unmet Need & Market Opportunity

CXU has the potential to restore native tissue across multiple high value markets

1 Platform
5+ Markets
20B+ Combined Global TAM

CXU™: This is Platform Economics

One patented formulation. Multiple applications.

One core platform with broad potential across multiple applications, including: wound care, aesthetics, oral health, veterinary health and 3D bioprinting. Our intellectual property and platform infrastructure provide the foundation for development over time.

Wound Care

Burns/Full-Thickness

$ 2.6B1

Aesthetics

Injectables

$ 11.0B2

Oral Health

Soft Tissue/Implants

$4.2B3

Animal Health

Wound Care

$ 1.4B4

3D Tissue

Inks & Tissue Scaffolds

$ 1.6B5

CXU™ is a New ECM Platform Technology

Changing Possibilities into Realities

Restoring and regenerating native tissue, with the opportunity to elevate the standard of care across multiple potential markets.

One Formula.
One Device.

One patented thermosensitive collagen-based ECM. One regulatory backbone. A single core asset designed to scale through staged clearance, not reformulation.

Staged Regulatory Architecture

Predicate-based 510(k) strategy designed to compress time-to-market and reduce regulatory spend versus PMA or de novo alternatives. A cleared lead device intended to establish substantial equivalence that subsequent indications may build upon.

One Technology,
Multiple Markets

Single-backbone scaffold designed to enable staged expansion across wound care, aesthetics, dental, veterinary, and 3D biomaterials from one core asset. Each indication is a distinct potential revenue stream sharing core IP and regulatory framework.

Validated Technology
Base (10+ Years R&D)

Decade-plus university-led preclinical evidence base with peer-reviewed publications across multiple tissue applications, designed to de-risk development and support predicate-based regulatory submissions.

Defensible IP (Patented in 40+ Countries)

100% assignment of all rights, title, and interest. Patent protection across 40+ countries with no licensing or royalty obligations. IP designed to protect core formulation, manufacturing process, and multi-indication application methods.

Capital-Efficient Scale (Manufacturing + Distribution)

Single production line designed to support multiple SKUs across indications. Shelf-stable, distribution-ready unit economics. Low-COGS manufacturing with minimal incremental capital expenditure per market entry.

The Conexeu Advantage

A regenerative tissue platform with a de-risked path to clearance, built for markets the legacy field cannot reach.

A Category-Defining Regenerative Platform

CXU™ is designed as the only injectable scaffold built for true tissue regeneration rather than transient volume replacement. The body provides cells and growth factors. CXU™ supplies the three-dimensional scaffold. One patented formulation. One device. A foundation built to scale across multiple indications without reformulation.

A De-Risked, Predicate-Based Regulatory Path

  • Pathway. Existing bovine collagen 510(k) predicates designed to compress timelines and reduce regulatory spend versus PMA or de novo alternatives.
  • Mechanism. A cleared lead device intended to establish a safety and substantial-equivalence foundation. Collagen-agnostic formulation designed to support bioequivalence across variants. Liquid-to-gel transition validated in the cleared predicate.
  • Sequencing. Lead clearance designed to support PreSub alignment with FDA. PreSub strategy intended to streamline subsequent indication clearances.

Emerging Demand the Legacy Field Cannot Address

GLP-1-driven soft tissue loss and post-weight-loss reconstructive demand are creating a multi-billion-dollar knock-on economy. Legacy HA fillers and biostimulators are structurally locked out of large-volume regeneration. CXU™ is built for what they cannot reach.

Platform Economics Across Multi-Billion-Dollar Verticals

One patented scaffold designed to unlock five addressable markets: wound care, aesthetics, dental, veterinary, and 3D biomaterials. Each indication is a distinct potential revenue stream sharing core IP, regulatory framework, and manufacturing infrastructure. Each new market may leverage prior clearance data with minimal incremental spend.

Validated Science + Defensible IP

Decade-plus university-led preclinical evidence base with peer-reviewed publications across multiple tissue applications. Conexeu holds the 100% assignment: all rights, title, and interest in the platform IP, patented in 40+ countries with no royalty or licensing obligations. The science is published. The moat is owned.

Experienced Team + Capital-Efficient Scale

Conexeu is led by an experienced leadership team with deep expertise in biomaterials, regenerative medicine, prior FDA approval, medical device commercialization and category-defining product launches.

Regulatory Roadmap

One Platform. One Device.

A staged pathway designed to unlock multiple markets from a single asset

510(k) Predicate Strategy Advantage

  • Existing bovine collagen predicates may reduce initial regulatory spend.
  • Predicate strategy designed to compress timelines versus de novo or PMA alternatives.
  • A cleared CXU device would be intended to establish a safety profile and substantial equivalence. Collagen-agnostic formulation designed to support bioequivalence of human-derived version. Liquid-to-gel transition validated in cleared predicate; same mechanism across variants.

CXU Development

10 Years of Development

Developed over 10 years at the University of British Columbia.

The University of British Columbia logo

International Patents

Patents Granted

USA, Japan, EU, Australia, and Canada

11 Peer-reviewed Publications

Acta Biomaterialia, Advances in Wound Care, Biomedical Materials, Canadian Journal of Diabetes, Experimental Dermatology, Gels, Journal of Burn Care, Tissue Engineering, Transplantation

PubMed Logo

CXU is building to scale in multiple high-value markets with the potential of additional revenue streams (ortho/surgical)

Latest News

View All Press Releases
Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing
Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU™ Wound Care Program
Conexeu Sciences to Ring Nasdaq Bell on June 10, 2026

Latest Financial Results

Q2 2026

Quarter Ended

Stock Information

View Quote and Chart info

1. Source: Market. Us, "Wound Care Devices Market Size, Share, Growth — CAGR of 4.8%," Updated January 5, 2026. Market valued at USD 2.6 billion (2023), projected USD 4.2 billion by 2033. Available at: https://media.market.us/wound-care-devices-market-news

2. Source: Grand View Research, "Aesthetic Injectable Market Size, Share & Trends Analysis Report By Product, By Application, By End-use, By Region, And Segment Forecasts, 2024–2030," Report ID: GVR-4-68040-275-9. Available at: https://www.grandviewresearch.com/industry-analysis/aesthetic-injectable-market-report

3. Source: Consegic Business Intelligence, "Gum Grafting Market — Size, Share, Industry Trends, and Forecasts (2025–2032)," Report ID: CBI_2168, Updated August 2025. Available at: https://www.consegicbusinessintelligence.com/gum-grafting-market

4. Source: VPA Research (via MarketResearch.com), "Animal Wound Care Market Size, Share, and Outlook, H2-2025 — By Product, By Animal, By End-User," Report ID: 42060937. Available at: https://www.marketresearch.com/VPA-Research-v4245/Animal-Wound-Care-Size-Share-42060937/

5. Source: Global Market Insights, "3D Bioprinting Market Size & Share Report, 2024–2032." Available at: https://www.gminsights.com/industry-analysis/3d-bioprinting-market